VERTEX PHARMACEUTICALS INC / MA Equity Securities, FV-NI, Unrealized Gain (Loss)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$12.20 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2025-11-04
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was -$2.60M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-06-30 was $5.40M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-03-31 was -$15.00M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-12-31 was -$7.20M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$57.70M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$600.00K.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$149.10M, a 971.93% decline from fiscal 2021.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain (loss) for fiscal 2021 was $17.10M, a 94.52% decline from fiscal 2020.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | -$2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.80M derived: sum of 2 quarters · filed 2025-11-04 | -$12.20M 10-Q · filed 2025-11-04 | -$19.40M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2025-06-30 | $5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$9.60M 10-Q · filed 2025-08-05 | -$16.80M derived: sum of 3 quarters · filed 2025-08-05 | -$27.60M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2025-03-31 | -$15.00M 10-Q · filed 2025-05-06 | -$22.20M derived: sum of 2 quarters · filed 2025-05-06 | -$33.00M derived: sum of 3 quarters · filed 2025-11-04 | -$45.70M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2024-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$18.00M derived: sum of 2 quarters · filed 2025-11-04 | -$30.70M derived: sum of 3 quarters · filed 2025-11-04 | -$57.70M 10-K · filed 2025-02-13 | ||||
| 2024-09-30 | -$10.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$23.50M derived: sum of 2 quarters · filed 2025-11-04 | -$50.50M 10-Q · filed 2025-11-04 | -$50.90M derived: sum of 4 quarters · filed 2025-11-04 | ||||
| 2024-06-30 | -$12.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$39.70M 10-Q · filed 2025-08-05 | -$40.10M derived: sum of 3 quarters · filed 2025-08-05 | -$46.30M derived: sum of 4 quarters · filed 2025-08-05 | ||||
| 2024-03-31 | -$27.00M 10-Q · filed 2025-05-06 | -$27.40M derived: sum of 2 quarters · filed 2025-05-06 | -$33.60M derived: sum of 3 quarters · filed 2025-05-06 | -$34.00M derived: sum of 4 quarters · filed 2025-05-06 | ||||
| 2023-12-31 | -$400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$6.60M derived: sum of 2 quarters · filed 2025-02-13 | -$7.00M derived: sum of 3 quarters · filed 2025-02-13 | -$600.00K 10-K · filed 2025-02-13 | ||||
| 2023-09-30 | -$6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$6.60M derived: sum of 2 quarters · filed 2024-11-05 | -$200.00K 10-Q · filed 2024-11-05 | -$6.20M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $6.00M 10-Q · filed 2024-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-02-13 | $16.70M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $6.40M 10-Q · filed 2024-05-07 | $400.00K derived: sum of 2 quarters · filed 2025-02-13 | $17.10M derived: sum of 3 quarters · filed 2025-02-13 | -$67.10M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $10.70M derived: sum of 2 quarters · filed 2025-02-13 | -$73.50M derived: sum of 3 quarters · filed 2025-02-13 | -$149.10M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $16.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$67.50M derived: sum of 2 quarters · filed 2023-11-07 | -$143.10M 10-Q · filed 2023-11-07 | -$131.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | -$84.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$159.80M 10-Q · filed 2023-08-02 | -$147.70M derived: sum of 3 quarters · filed 2024-02-15 | -$101.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | -$75.60M 10-Q · filed 2023-05-02 | -$63.50M derived: sum of 2 quarters · filed 2024-02-15 | -$16.80M derived: sum of 3 quarters · filed 2024-02-15 | -$6.20M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $58.80M derived: sum of 2 quarters · filed 2024-02-15 | $69.40M derived: sum of 3 quarters · filed 2024-02-15 | $17.10M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $46.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $57.30M derived: sum of 2 quarters · filed 2022-10-28 | $5.00M 10-Q · filed 2022-10-28 | $4.99M 10-Q · filed 2021-11-03 | $176.03M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | $10.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$41.70M 10-Q · filed 2022-08-05 | -$41.69M 10-Q · filed 2021-07-30 | $129.33M derived: sum of 3 quarters · filed 2023-02-10 | $205.08M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | -$52.30M 10-Q · filed 2022-05-06 | -$52.30M 10-Q · filed 2021-04-30 | $118.73M derived: sum of 2 quarters · filed 2023-02-10 | $194.48M derived: sum of 3 quarters · filed 2023-02-10 | $304.47M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $171.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $246.78M derived: sum of 2 quarters · filed 2023-02-10 | $356.77M derived: sum of 3 quarters · filed 2023-02-10 | $311.90M 10-K · filed 2023-02-10 | $311.94M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $75.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $185.74M derived: sum of 2 quarters · filed 2021-11-03 | $140.87M 10-Q · filed 2021-11-03 | $269.60M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $109.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $65.12M 10-Q · filed 2021-07-30 | $193.85M derived: sum of 3 quarters · filed 2022-02-09 | $162.64M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | -$44.87M 10-Q · filed 2021-04-30 | $83.87M derived: sum of 2 quarters · filed 2022-02-09 | $52.65M derived: sum of 3 quarters · filed 2022-02-09 | $109.18M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $128.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $97.52M derived: sum of 2 quarters · filed 2022-02-09 | $154.05M derived: sum of 3 quarters · filed 2022-02-09 | $197.60M 10-K · filed 2022-02-09 | $197.60M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | -$31.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $25.31M derived: sum of 2 quarters · filed 2020-10-30 | $68.86M 10-Q · filed 2020-10-30 | -$16.80M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $56.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $100.08M 10-Q · filed 2020-07-31 | $14.42M derived: sum of 3 quarters · filed 2021-02-11 | -$46.74M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $43.55M 10-Q · filed 2020-05-01 | -$42.11M derived: sum of 2 quarters · filed 2021-02-11 | -$103.27M derived: sum of 3 quarters · filed 2021-02-11 | -$49.35M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | -$85.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$146.82M derived: sum of 2 quarters · filed 2021-02-11 | -$92.90M derived: sum of 3 quarters · filed 2021-02-11 | $2.56M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | -$61.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$7.24M derived: sum of 2 quarters · filed 2019-10-31 | $88.22M 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | $53.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $149.38M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $95.46M 10-Q · filed 2019-05-01 | |||||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |